|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administeredBy
|
subcutaneous injection
|
|
gptkbp:approvedBy
|
2015
|
|
gptkbp:approvedDrugs
|
gptkb:alirocumab
gptkb:evolocumab
inclisiran
|
|
gptkbp:clinicalTrialPhase
|
gptkb:ODYSSEY
gptkb:FOURIER
|
|
gptkbp:contraindication
|
hypersensitivity to ingredients
|
|
gptkbp:cost
|
high
|
|
gptkbp:discoveredBy
|
medical researchers
|
|
gptkbp:drugClass
|
gptkb:monoclonal_antibody
siRNA (for inclisiran)
|
|
gptkbp:duration
|
long-acting
|
|
gptkbp:effect
|
reduce LDL cholesterol by 50-60%
|
|
gptkbp:effectOnCardiovascularEvents
|
reduces risk
|
|
gptkbp:effectOnHDL
|
modest increase
|
|
gptkbp:effectOnTriglycerides
|
modest reduction
|
|
gptkbp:frequency
|
every 2-4 weeks
every 6 months (inclisiran)
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
PCSK9 inhibitors
|
|
gptkbp:marketedAs
|
gptkb:Sanofi
gptkb:Regeneron
gptkb:Amgen
gptkb:Novartis
|
|
gptkbp:mechanismOfAction
|
increase LDL receptor recycling
increase clearance of LDL cholesterol
inhibit PCSK9 protein
|
|
gptkbp:notableBrand
|
gptkb:Repatha
gptkb:Praluent
gptkb:Leqvio
|
|
gptkbp:notRecommendedFor
|
children under 12 (most cases)
|
|
gptkbp:prescribes
|
gptkb:familial_hypercholesterolemia
atherosclerotic cardiovascular disease
statin intolerance
|
|
gptkbp:prescriptionStatus
|
prescription only
|
|
gptkbp:regulates
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:relatedTo
|
gptkb:ezetimibe
statins
|
|
gptkbp:routeOfAdministration
|
subcutaneous
|
|
gptkbp:sideEffect
|
injection site reactions
nasopharyngitis
flu-like symptoms
|
|
gptkbp:storage
|
refrigeration required
|
|
gptkbp:target
|
gptkb:PCSK9_protein
|
|
gptkbp:usedFor
|
prevention of cardiovascular disease
lowering LDL cholesterol
treatment of hypercholesterolemia
|
|
gptkbp:bfsParent
|
gptkb:LDL_receptor
gptkb:familial_hypercholesterolemia
gptkb:Lipoprotein(a)
|
|
gptkbp:bfsLayer
|
6
|